Exicure (XCUR) Income towards Parent Company (2016 - 2026)
Exicure (XCUR) reported Income towards Parent Company of -$1.8 million for Q1 2026, down 160.73% on a YoY basis from $3.0 million in Q1 2025, and up 36.92% quarter-over-quarter from -$2.9 million in Q4 2025.
Exicure (XCUR) Income towards Parent Company (2016 - 2026) Analysis & Trends
Exicure has reported Income towards Parent Company for 11 years, with the latest figure at -$1.8 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company fell 160.73% year-over-year to -$1.8 million; the trailing twelve-month figure through Mar 2026 stood at -$9.8 million (down 66.91% YoY), and the FY2025 full-year result was -$4.9 million, up 49.02% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$1.8 million, up from -$2.9 million in the prior quarter.
- The five-year high for Income towards Parent Company was $18.4 million in Q4 2022, with the low at -$8.3 million in Q1 2022.
- Historically, Income towards Parent Company has averaged -$2.1 million across 5 years, with a median of -$2.6 million in 2025.
- Annual changes were most pronounced in 2024 — Income towards Parent Company sank 382.92% — and 2025, when it jumped 463.09%.
- Exicure's Income towards Parent Company stood at $18.4 million in 2022, then slumped by 108.08% to -$1.5 million in 2023, then sank by 382.92% to -$7.2 million in 2024, then jumped by 59.64% to -$2.9 million in 2025, then surged by 36.92% to -$1.8 million in 2026.
- The last three Income towards Parent Company figures came in at -$1.8 million (Q1 2026), -$2.9 million (Q4 2025), and -$2.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Exicure | 17.53 Mn | 14.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.83 Mn |
| Dec 31, 2025 | -2.90 Mn |
| Sep 30, 2025 | -2.44 Mn |
| Jun 30, 2025 | -2.62 Mn |
| Mar 31, 2025 | 3.01 Mn |
| Dec 31, 2024 | -7.18 Mn |
| Sep 30, 2024 | -1.09 Mn |
| Jun 30, 2024 | -600,000.00 |
| Mar 31, 2024 | -829,000.00 |
| Dec 31, 2023 | -1.49 Mn |
| Sep 30, 2023 | -5.26 Mn |
| Jun 30, 2023 | -5.76 Mn |
| Mar 31, 2023 | -4.41 Mn |
| Dec 31, 2022 | 18.40 Mn |
| Sep 30, 2022 | -5.16 Mn |
| Jun 30, 2022 | -7.47 Mn |
| Mar 31, 2022 | -8.35 Mn |
| Dec 31, 2021 | -13.83 Mn |
| Sep 30, 2021 | -23.53 Mn |
| Jun 30, 2021 | -14.27 Mn |